• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib.

作者信息

Wenn K, Tomala L, Wilop S, Vankann L, Hasenbank C, Frank O, Hochhaus A, Giles F J, Lange T, Müller M C, Koschmieder S, Beier F, Ziegler P, Brümmendorf T H

机构信息

Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.

Novartis Pharma GmbH, Nürnberg, Germany.

出版信息

Leukemia. 2015 Dec;29(12):2402-4. doi: 10.1038/leu.2015.245. Epub 2015 Sep 15.

DOI:10.1038/leu.2015.245
PMID:26369986
Abstract
摘要

相似文献

1
Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib.慢性期慢性髓性白血病（CML-CP）诊断时的端粒长度可识别出一个亚组，该亚组在接受尼洛替尼治疗12个月后，根据欧洲白血病网络（ELN）标准具有良好的预后参数和分子反应。
Leukemia. 2015 Dec;29(12):2402-4. doi: 10.1038/leu.2015.245. Epub 2015 Sep 15.
2
Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase.伊马替尼一线治疗后使用尼罗替尼：慢性期慢性髓性白血病患者的真实纵向队列研究
Br J Haematol. 2018 Feb;180(3):356-364. doi: 10.1111/bjh.15042. Epub 2017 Dec 19.
3
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.尼洛替尼与达沙替尼二线治疗慢性期慢性髓性白血病患者的真实世界比较。
Ann Hematol. 2021 May;100(5):1213-1219. doi: 10.1007/s00277-021-04477-0. Epub 2021 Mar 7.
4
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.评价一线尼洛替尼治疗后达到完全细胞遗传学缓解的慢性髓性白血病患者体内残留的 CD34(+) Ph(+)祖细胞。
Cancer. 2012 Nov 1;118(21):5265-9. doi: 10.1002/cncr.27506. Epub 2012 Apr 19.
5
NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib.尼洛替尼治疗的慢性期慢性髓性白血病（CML-CP）早期患者中自然杀伤（NK）细胞动力学及其与分子反应的关联
Leukemia. 2017 Oct;31(10):2264-2267. doi: 10.1038/leu.2017.235. Epub 2017 Jul 10.
6
[STI 571 for treating 19 patients with chronic-phase chronic myeloid leukemia].
Di Yi Jun Yi Da Xue Xue Bao. 2003 Nov;23(11):1149-50.
7
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.尼洛替尼治疗伊马替尼耐药或不耐受的慢性期慢性髓性白血病患者有效：24 个月随访结果。
Blood. 2011 Jan 27;117(4):1141-5. doi: 10.1182/blood-2010-03-277152. Epub 2010 Nov 22.
8
Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR ): The phase 2, multicenter N-Road study.基于早期获得深度分子学应答（MR）的新诊断慢性期慢性髓性白血病患者接受尼洛替尼的最佳治疗策略：Ⅱ期、多中心 N-Road 研究。
Cancer Med. 2020 Jun;9(11):3742-3751. doi: 10.1002/cam4.3034. Epub 2020 Apr 6.
9
Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.尼洛替尼对比伊马替尼治疗中国新诊断慢性期慢性髓性白血病患者的3期研究：ENESTchina研究
Blood. 2015 Apr 30;125(18):2771-8. doi: 10.1182/blood-2014-09-601674. Epub 2015 Mar 12.
10
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.慢性期慢性髓性白血病患者对伊马替尼反应欠佳时，换用尼罗替尼与伊马替尼剂量递增的比较（LASOR）：一项随机、开放标签试验
Lancet Haematol. 2016 Dec;3(12):e581-e591. doi: 10.1016/S2352-3026(16)30167-3.

引用本文的文献

1
The Telomere Length Signature in Leukemias-From Molecular Mechanisms Underlying Telomere Shortening to Immunotherapeutic Options Against Telomerase.白血病中的端粒长度特征——从端粒缩短的分子机制到针对端粒酶的免疫治疗选择
Cancers (Basel). 2025 Jun 10;17(12):1936. doi: 10.3390/cancers17121936.
2
Advancements in leukemia management: Bridging diagnosis, prognosis and nanotechnology (Review).白血病管理的进展：连接诊断、预后和纳米技术（综述）。
Int J Oncol. 2024 Dec;65(6). doi: 10.3892/ijo.2024.5700. Epub 2024 Oct 4.
3
LARP3, LARP7, and MePCE are involved in the early stage of human telomerase RNA biogenesis.

本文引用的文献

1
Direct comparison of flow-FISH and qPCR as diagnostic tests for telomere length measurement in humans.作为人类端粒长度测量诊断测试的流式荧光原位杂交技术（flow-FISH）和定量聚合酶链反应（qPCR）的直接比较。
PLoS One. 2014 Nov 19;9(11):e113747. doi: 10.1371/journal.pone.0113747. eCollection 2014.
2
Epigenetic aging upon allogeneic transplantation: the hematopoietic niche does not affect age-associated DNA methylation.异基因移植后的表观遗传衰老：造血微环境不影响与年龄相关的DNA甲基化。
Leukemia. 2015 Apr;29(4):985-8. doi: 10.1038/leu.2014.323. Epub 2014 Nov 12.
3
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
LARP3、LARP7 和 MePCE 参与人类端粒酶 RNA 生物发生的早期阶段。
Nat Commun. 2024 Jul 15;15(1):5955. doi: 10.1038/s41467-024-50422-w.
4
Telomere biology: from disorders to hematological diseases.端粒生物学：从疾病到血液学疾病
Front Oncol. 2023 May 19;13:1167848. doi: 10.3389/fonc.2023.1167848. eCollection 2023.
5
The interplay between telomeric complex members and BCR::ABL1 oncogenic tyrosine kinase in the maintenance of telomere length in chronic myeloid leukemia.端粒复合物成员与 BCR::ABL1 致癌酪氨酸激酶在慢性髓细胞白血病中端粒长度维持中的相互作用。
J Cancer Res Clin Oncol. 2023 Aug;149(10):7103-7112. doi: 10.1007/s00432-023-04662-w. Epub 2023 Mar 5.
6
Telomere length dynamics measured by flow-FISH in patients with obesity undergoing bariatric surgery.通过流式荧光原位杂交技术测量肥胖症患者接受减肥手术后端粒体长度的动态变化。
Sci Rep. 2023 Jan 6;13(1):304. doi: 10.1038/s41598-022-27196-6.
7
Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients.端粒长度对慢性髓性白血病患者使用伊马替尼实现深度分子反应的影响。
Hemasphere. 2021 Nov 30;5(12):e657. doi: 10.1097/HS9.0000000000000657. eCollection 2021 Dec.
8
Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy.外周血白细胞端粒缩短与接受免疫检查点抑制剂治疗的癌症患者生存率低相关。
Front Oncol. 2021 Aug 19;11:729207. doi: 10.3389/fonc.2021.729207. eCollection 2021.
9
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?酪氨酸激酶抑制剂在慢性髓性白血病中的停药：何时及针对谁？
Haematologica. 2020 Dec 1;105(12):2738-2745. doi: 10.3324/haematol.2019.242891.
10
Interleukin-6, -8, and TGF-β Secreted from Mesenchymal Stem Cells Show Functional Role in Reduction of Telomerase Activity of Leukemia Cell Via Wnt5a/β-Catenin and P53 Pathways.间充质干细胞分泌的白细胞介素-6、-8和转化生长因子-β通过Wnt5a/β-连环蛋白和P53途径在降低白血病细胞端粒酶活性中发挥功能作用。
Adv Pharm Bull. 2020 Jun;10(2):307-314. doi: 10.34172/apb.2020.037. Epub 2020 Feb 18.
欧洲白血病网络关于慢性髓性白血病管理的建议：2013 年版。
Blood. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569. Epub 2013 Jun 26.
4
The telomere syndromes.端粒综合征。
Nat Rev Genet. 2012 Oct;13(10):693-704. doi: 10.1038/nrg3246. Epub 2012 Sep 11.
5
Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation.端粒延长与雄激素治疗再生障碍性贫血伴杂合性 hTERT 基因突变患者的临床反应
Ann Hematol. 2012 Jul;91(7):1115-20. doi: 10.1007/s00277-012-1454-x. Epub 2012 Apr 4.
6
Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy.慢性髓系白血病中的端粒与端粒酶：对发病机制、疾病进展及靶向治疗的影响
Hematol Oncol. 2009 Sep;27(3):123-9. doi: 10.1002/hon.901.
7
Concise review: Telomere biology in normal and leukemic hematopoietic stem cells.简明综述：正常及白血病造血干细胞中的端粒生物学
Stem Cells. 2007 Aug;25(8):1853-61. doi: 10.1634/stemcells.2007-0057. Epub 2007 May 17.
8
Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia.端粒缩短与慢性髓性白血病诊断时的预后评分相关，且在疾病进展过程中迅速缩短。
Leuk Lymphoma. 2004 Sep;45(9):1775-81. doi: 10.1080/10428190410001693542.
9
Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia.在伊马替尼治疗下，先前缩短的端粒长度恢复正常，这表明慢性髓性白血病患者正常造血干细胞中不存在预先存在的端粒长度缺陷。
Ann N Y Acad Sci. 2003 May;996:26-38. doi: 10.1111/j.1749-6632.2003.tb03229.x.
10
Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia.
Blood. 2003 Jan 1;101(1):375-6. doi: 10.1182/blood-2002-08-2557.